CARsgen Therapeutics Holdings (HKSE:02171) Cash Flow for Dividends: HK$0.0 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02171 CARsgen Therapeutics Holdings Ltd HKSE:02171
32 GF Score
Price HK$14.90
! 3 Warning Signs
View Full Analysis

What is CARsgen Therapeutics Holdings Cash Flow for Dividends?

CARsgen Therapeutics Holdings HKSE:02171 +1.36% 32 Cash Flow for Dividends is HK$0.0 Mil as of Dec. 2025. GuruFocus rates HKSE:02171 with a GF Score™ of 32/100. The stock has 3 warning signs investors should review.

CARsgen Therapeutics Holdings's cash flow for dividends for the six months ended in Dec. 2025 was HK$0.0 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.0 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

CARsgen Therapeutics Holdings Cash Flow for Dividends Related Terms

CARsgen Therapeutics Holdings Cash Flow for Dividends Historical Data

* Premium members only.

The historical data trend for CARsgen Therapeutics Holdings's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CARsgen Therapeutics Holdings Cash Flow for Dividends Chart

CARsgen Therapeutics Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow for Dividends
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

CARsgen Therapeutics Holdings Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
HKSE:02171
32GF Score
CARsgen Therapeutics Holdings Ltd HKSE:02171
Cash Flow for Dividends is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CARsgen Therapeutics Holdings Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Dividends of HK$0.0 Mil mean?
CARsgen Therapeutics Holdings (HKSE:02171) has a Cash Flow for Dividends of HK$0.0 Mil as of Dec. 2025. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for CARsgen Therapeutics Holdings and its competitors.
Is CARsgen Therapeutics Holdings' Cash Flow for Dividends too high?
CARsgen Therapeutics Holdings' current Cash Flow for Dividends is HK$0.0 Mil. Overall, CARsgen Therapeutics Holdings has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does CARsgen Therapeutics Holdings' Cash Flow for Dividends compare to VRTX and REGN?
CARsgen Therapeutics Holdings' Cash Flow for Dividends of HK$0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Biotechnology company?
A good Cash Flow for Dividends depends on the Biotechnology industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for CARsgen Therapeutics Holdings and its competitors. CARsgen Therapeutics Holdings's current Cash Flow for Dividends is HK$0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CARsgen Therapeutics Holdings stock overvalued right now?
CARsgen Therapeutics Holdings (HKSE:02171) has a current Cash Flow for Dividends of HK$0.0 Mil. The current Cash Flow for Dividends is HK$0.0 Mil. CARsgen Therapeutics Holdings' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For CARsgen Therapeutics Holdings (HKSE:02171), the current Cash Flow for Dividends is HK$0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CARsgen Therapeutics Holdings Business Description

Other Exchanges CRTHF:USA
Address No. 466 Yindu Road, Building 2, 1st Floor, Xuhui District, Shanghai, CHN
CARsgen Therapeutics Holdings Ltd is a clinical-stage biopharmaceutical company discovering, researching, and developing cell therapies in the People's Republic of China and the United States of America. During the year, a majority of the Group's revenue was derived from one customer located in the Chinese mainland.
32GF Score

Get the complete analysis for HKSE:02171

Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$14.90
Price